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Abstract:  
Understanding the biologic milieu associated with differing symptom profiles in allogeneic 
HSCT survivors with cGVHD has the potential to clarify the pathogenesis of cGVHD activity 
and tissue damage, and may direct the development of new strategies to ameliorate symptoms 
and improve quality of life. 
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Article: 
Background: Understanding the biologic milieu associated with differing symptom profiles in 
allogeneic HSCT survivors with cGVHD has the potential to clarify the pathogenesis of cGVHD 
activity and tissue damage, and may direct the development of new strategies to ameliorate 
symptoms and improve quality of life. 
Objective: To determine if differing cGVHD symptom profiles are associated with unique 
patterns of pro-inflammatory cytokine expression and markers of systemic immune activation. 
Methods: Plasma levels of sBAFF, IL-1β, IL-1 receptor antagonist, IL-6, soluble IL-6 receptor, 
soluble TNF-receptor II, MCP-1, and MIG were assayed by sandwich ELISA. Lymphocyte 
subset quantities were measured. Concurrently, the Lee Chronic GVHD Symptom Scale, a self-
report measure of cGVHD symptoms, and clinical data were obtained. Data from 79 patients 
were analyzed using descriptive statistics, latent profile analysis, and multinomial logistic 
regression. 
Results: Three distinct symptom subgroups were identified through latent profile analysis: 
Group 1 (low on all symptoms), Group 2 (prominent oral, upper GI, and weight loss symptoms); 
and Group 3 (eye, muscle/joint, fatigue and mood symptoms). Multinomial logistic regression, 
controlling for age, length of time since transplant, cGVHD severity, intensity of 
immunosuppression and post-transplant lymphocyte reconstitution, revealed that IL-6, TNF-RII, 
MCP-1 and sBAFF levels significantly distinguished the three symptom subgroups. 
Odds Ratios and 95% Confidence Intervals for the Multinomial Logistic Regression of Symptom Latent Class 
Membership on Cytokines † Controlling for Age, Time Since Transplant, cGVHD Severity, Intensity of Current 
Immunosuppression and Absolute Lymphocyte Counts † 
 
 Symptom Profile 1 (low on 
all symptoms) vs. Symptom 
Profile 2 (prominent oral/GI 
symptoms) OR (95% CI) 
Symptom Profile 1 (low on all 
symptoms) vs. Symptom Profile 3 
(prominent eye, muscle/joint, fatigue 
and mood symptoms) OR (95% CI) 
Symptom Profile 2 (prominent oral/GI 
symptoms) vs. Symptom Profile 3 
(prominent eye, muscle/joint, fatigue 
and mood symptoms) OR (95% CI) 
IL-1 β 1.59 (0.30-8.45) 0.92 (0.32-2.60) 0.58 (0.10-3.32) 
IL-6 0.27 (0.09-0.79)∗ 1.15 (0.52-2.52) 4.26 (1.32-13.82)∗ 
IL-1 
RA 
0.69 (0.22-2.14) 0.55 (0.29-1.07) 0.81 (0.26-2.48) 
sIL-6R 0.50 (0.12-2.13) 1.78 (0.54-5.90) 3.53 (0.83-15.13) 
TNF-
RII 
0.29 (0.04-2.42) 0.28 (0.08-0.99)∗ 0.95 (0.12-7.59) 
MCP-1 8.70 (1.46-51.66)∗ 0.40 (0.11-1.40) 0.05 (0.01-0.36)∗∗ 
MIG 1.33 (0.73-2.44) 1.02 (0.63-1.65) 0.77 (0.42-1.39) 
sBAFF 0.40 (0.13-1.30) 1.86 (0.88-3.93) 4.61 (1.39-15.31)∗∗ 
† values were log normal transformed prior to analysis 
∗∗ 
or 
∗ 
p < .01 or p < .05, respectively, multinomial logistic regression. 
 
Higher IL-6 levels significantly differentiated participants in Group 2 from those in Groups 1 and 
3. Group 3 had higher TNF-RII compared to Group 1. Those with higher sBAFF levels were 
significantly more likely to be in Group 2, while those with higher MCP-1 levels were 
significantly more likely to be in Group 3. 
Conclusion: Allogeneic HSCT survivors with differing cGVHD symptom profiles were 
distinguished by significantly different levels of IL-6, TNF-RII, MCP-1 and sBAFF. These data 
validate this new symptom grouping system based on the Lee Chronic GVHD Symptom Scale as 
a measure of cGVHD disease burden. IL-6, TNF-RII, MCP-1 and sBAFF appear to be important 
biomarkers that reflect specific cGVHD manifestations and merit further study. 
